Shattuck Labs Reports Q1 2025: Net Loss Narrowed to $13.7M, EPS Improved to $0.27
Shattuck Labs Inc., a biotechnology company, has announced its financial results for the first quarter of 2025. The company reported a net loss of $13.7 million for the quarter ended March 31, 2025, compared to a net loss of $18.5 million for the same quarter in 2024. The cash and cash equivalents, along with investments, stood at $60.9 million as of March 31, 2025, down from $114.6 million as of March 31, 2024. Research and Development expenses were recorded at $9.9 million, a decrease from $16.3 million in the previous year's corresponding quarter. General and Administrative expenses also saw a reduction, amounting to $4.5 million compared to $4.9 million in the first quarter of 2024. A significant business update includes the advancement of Shattuck's SL-325 program, with an Investigational New Drug $(IND.AU)$ filing anticipated in the third quarter of 2025. The company also participated in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, with CEO Taylor Schreiber presenting at the event. Shattuck's current cash balance is expected to fund operations into 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9443124-en) on May 01, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.